Recruiting Epilepsy Studies in Lancaster
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy....
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label...
About Epilepsy Clinical Trials in Lancaster
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It affects about 50 million people worldwide. Treatment includes antiseizure medications, surgery, and neurostimulation devices.
There are currently 2 epilepsy clinical trials recruiting participants in Lancaster, PENNSYLVANIA. These studies are seeking a combined 632 participants. Research is being sponsored by Biohaven Therapeutics Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Epilepsy Clinical Trials in Lancaster — FAQ
Are there epilepsy clinical trials in Lancaster?
Yes, there are 2 epilepsy clinical trials currently recruiting in Lancaster, PENNSYLVANIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lancaster?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lancaster research site will contact you about next steps.
Are clinical trials in Lancaster free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lancaster studies also compensate for your time and travel.
What epilepsy treatments are being tested?
The 2 active trials in Lancaster are testing new therapies including novel drugs, biologics, and treatment approaches for epilepsy.
Data updated March 2, 2026 from ClinicalTrials.gov